LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Home・Lista de Ações・Merck & Co Inc.

Merck & Co Inc.

Fechado

SetorSaúde

112.58 1.16

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

110.97

Máximo

112.86

Indicadores-chave
By Trading Economics
Rendimento	-7.2B -4.2B
Vendas	-114M 16B
P/E Médio do Setor	31.347 51.415
EPS	-1.28
Rendimento de Dividendos	2.94
Margem de lucro	-26.053
Funcionários	73,000
EBITDA	-6.2B -1.9B

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+21.75% upside

Dividendos
By Dow Jones
Rendimento de Dividendos Médio do Setor	2.94% 2.34%
Próximos Ganhos	4 de ago. de 2026
Próxima data de dividendos	7 de jul. de 2026
Próxima data de ex-dividendo	15 de jun. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	2.6B 275B
Abertura anterior	111.42
Fecho anterior	112.58

Sentimento de Notícias

By Acuity

54%

46%

249 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

76.03 / 83.28 Suporte e Resistência

Merck & Co Inc. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

30 de abr. de 2026, 14:20 UTC

Ganhos

Merck 1Q Sales Rise on Continued Keytruda Growth -- Update

30 de abr. de 2026, 10:45 UTC

Ganhos

Merck 1Q Sales Rise on Continued Keytruda Growth

5 de mai. de 2026, 18:12 UTC

Ganhos

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 de mai. de 2026, 13:54 UTC

Ganhos

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 de mai. de 2026, 12:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Merck Cites Costs Associated With Advancing TERN-701 and Financing >MRK

5 de mai. de 2026, 12:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Merck: GAAP and Adj EPS Expected to Be Negatively Impacted by About 12c/Shr in 2026 >MRK

5 de mai. de 2026, 12:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Merck: Transaction Expected to Be Accounted for as Asset Acquisition, Resulting in Chg of About $5.8 B, or $2.35/Shr, Included in 2Q and FY26 Results >MRK

5 de mai. de 2026, 12:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Merck Completes Acquisition Of Terns Pharmaceuticals, Inc. >MRK TERN

1 de mai. de 2026, 18:35 UTC

Ganhos

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 de mai. de 2026, 14:53 UTC

Ganhos

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

30 de abr. de 2026, 13:27 UTC

Ganhos

Merck Stock Falls After Earnings. It's Working on Ways to Blunt Future Lost Keytruda Sales. -- Barrons.com

30 de abr. de 2026, 10:47 UTC

Ganhos

Update: Merck Stock Rises on Earnings. These Problems Loom Larger Than Keytruda Patent Cliff. -- Barrons.com

30 de abr. de 2026, 10:30 UTC

Ganhos

Merck: Also Anticipate EPS Will Be Negatively Affected by About 12c Over Remainder of 2026 Following Close of Terns Deal >MRK

30 de abr. de 2026, 10:30 UTC

Ganhos

Merck Raises 2026 View To Adj EPS $5.04-Adj EPS $5.16 Vs Prior View $5-$5.15 >MRK

30 de abr. de 2026, 10:30 UTC

Ganhos

Merck: 2026 Outlook Doesn't Reflect Any Impact From Proposed Acquisition of Terns Pharmaceuticals, Which Is Expected to Close in May and Result in One-Time Charge of About $2.35/Shr >MRK

30 de abr. de 2026, 10:30 UTC

Ganhos

Merck: Sales Outlook Includes Positive Impact From Forex of About 1% at Mid-April 2026 Exchange Rates >MRK

30 de abr. de 2026, 10:30 UTC

Ganhos

Merck: Adj EPS Outlook Also Reflects One-Time Charge of $3.62/Shr for Acquisition of Cidara >MRK

30 de abr. de 2026, 10:30 UTC

Ganhos

Merck: Adj EPS Outlook Includes Positive Impact From Forex of About 10c/Shr at Mid-April 2026 Exchange Rates >MRK

30 de abr. de 2026, 10:30 UTC

Ganhos

Merck Narrows 2026 View To Sales $65.8B-$67B Vs Prior View $65.5B-$67B >MRK

30 de abr. de 2026, 10:30 UTC

Ganhos

Merck: Latest 1Q Includes Charge of $3.62/Share for the Acquisition of Cidara >MRK

30 de abr. de 2026, 10:30 UTC

Ganhos

Merck: 1Q Gardasil/Gardasil 9 Sales Also Reflect Lower Sales in U.S. Primarily Due to Unfavorable Public-Sector Purchasing Patterns, Partially Offset by Higher Net Pricing >MRK

30 de abr. de 2026, 10:30 UTC

Ganhos

Merck 1Q Gardasil/Gardasil 9 Sales Down 19% >MRK

30 de abr. de 2026, 10:30 UTC

Ganhos

Merck: Lower 1Q Januvia/Janumet Sales Due to Lower Demand and Net Pricing in U.S., Lower Demand in China and Most Other International Markets Due to Generic Competition >MRK

30 de abr. de 2026, 10:30 UTC

Ganhos

Merck: Pleased With Progress and Excited for What's Ahead, as We Enter Particularly Robust Period of Phase 3 Data Readouts and Deliver on Promise of Our Pipeline for Patients >MRK

30 de abr. de 2026, 10:30 UTC

Ganhos

Merck 1Q Winrevair Sales $525M, Up 88%, Reflecting Continued Uptake in U.S. and Early Launch Uptake in Certain Intl Mkts, Especially Japan and Europe >MRK

30 de abr. de 2026, 10:30 UTC

Ganhos

Merck: 1Q Animal Health Sales Growth Attributable to Performance in Both Livestock and Companion Animal Product Portfolios >MRK

30 de abr. de 2026, 10:30 UTC

Ganhos

Merck: Lower 1Q Gardasil/Gardasil 9 Sales Primarily Due to Lower Demand in China as Well as Lower Sales in Japan Following National Catch-Up Immunization Program >MRK

30 de abr. de 2026, 10:30 UTC

Ganhos

Merck 1Q Pharmaceutical Sales Up 5% >MRK

30 de abr. de 2026, 10:30 UTC

Ganhos

Merck 1Q Animal Health Sales Up 13% >MRK

30 de abr. de 2026, 10:30 UTC

Ganhos

Merck 1Q Sales $16.29B >MRK

Comparação entre Pares

Variação de preço

Merck & Co Inc. Previsão

Preço-alvo

By TipRanks

21.75% parte superior

Previsão para 12 meses

Média 135.61 USD 21.75%

Máximo 179 USD

Mínimo 112 USD

Com base em 20 analistas de Wall Street que oferecem metas de preço de 12 meses para Merck & Co Inc. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

20 ratings

Comprar

Manter

Vender

Com base em 20 analistas que deram avaliações de ações para Merck & Co Inc. - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

76.03 / 83.28Suporte e Resistência

Recent bearish events outweigh bullish events.

All events are bearish.

Sentimento

By Acuity

249 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.